Tectonic Therapeutic to Participate in September Investor Conferences
Rhea-AI Summary
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company focused on G-protein coupled receptors (GPCRs), has announced its participation in two major investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 4, featuring a fireside chat with CEO Alise Reicin at 3:45 PM ET. Additionally, Tectonic will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6, engaging in one-on-one investor meetings.
A live webcast of the Wells Fargo conference presentation will be available on Tectonic's website, with a replay accessible for approximately 90 days. These conferences provide Tectonic with opportunities to showcase its progress in developing therapeutic proteins and antibodies that modulate GPCR activity to potential investors and industry professionals.
Positive
- None.
Negative
- None.
News Market Reaction – TECX
In the trading session that priced this news, TECX declined 2.64%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024.
| 2024 Wells Fargo Healthcare Conference: | |
| Date: | September 4, 2024 |
| Time: | 3:45 PM ET |
| Presenter: | Alise Reicin, MD, President, CEO and Director, Tectonic Therapeutic |
| Format: | Fireside Chat |
| Morgan Stanley 22nd Annual Global Healthcare Conference: | |
| Date: | September 6, 2024 |
| Format: | Investor one-on-one meetings |
A live webcast of the fireside chat at the Wells Fargo Healthcare Conference can be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days.
About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary GEODe™ (“GPCRs Engineered for Optimal Discovery”) technology platform, Tectonic is focused on developing biologic medicines that have the potential to overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality or extend duration of life. Tectonic’s initial product candidate, TX000045 (TX45), is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is currently in a Phase 2 clinical trial and has the potential to address patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF), which affects over 600,000 people in the US alone, currently with no approved therapies. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow @TectonicTx on X (formerly Twitter) and LinkedIn.
Contacts:
Investors:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Media:
Karen Sharma
CG Life
ksharma@cglife.com
(617) 571-2733
